

October 27, 2025

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Tomohiro Iga, Executive Officer and General Manager of Corporate Division Tel: +81-3-6455-5308

CellSource's Blood-derived Processing Service Introduced at Hyogo Medical University Hospital, Department of Orthopedic Surgery

CellSource Co., Ltd. (Representative Director and CEO: Takashi Sawada; hereinafter referred to as the "Company") is pleased to announce that its blood-derived processing service has been introduced at the Department of Orthopedic Surgery, Hyogo Medical University Hospital (hereinafter, "Hyogo Medical University Hospital Orthopedic Surgery"), with the service scheduled to commence in October 2025.

The blood-derived processing service is a contract processing service in which PRP (platelet-rich plasma) prepared from a patient's blood, entrusted by medical institutions, is processed to remove cells and freeze-dried, enabling long-term storage at room temperature. The processed autologous blood-derived cytokine, "PFC-FD™," is expected to promote tissue repair, reduce pain, and restore function when administered locally. It is primarily used in the treatment of osteoarthritis and sports injuries in orthopedics, as well as infertility treatments in obstetrics and gynecology.

As of July 31, 2025, the cumulative number of contract processing cases handled by the Company exceeded 120,000, and the total number of affiliated medical institutions reached 2,057. With the introduction of this service at Hyogo Medical University Hospital Orthopedic Surgery, the Company can now offer a new treatment option to patients who have not seen sufficient results with conventional therapies or who seek further improvement.

Hyogo Medical University Hospital is an advanced treatment hospital equipped with the latest medical facilities and equipment, playing a significant role in regional medical care and consistently providing advanced treatment. Furthermore, as an educational institution promoting leading-edge research and medical education, it contributes significantly to the development of medicine. The introduction of the Company's service to such an advanced medical institution marks an important step in expanding the possibilities of regenerative medicine. Through collaboration with Hyogo Medical University Hospital Orthopedic Surgery, the Company expects to accumulate scientific evidence regarding the efficacy and

safety of PFC-FD™ therapy, thereby enabling the provision of optimal treatments to more patients.

The Company will continue to ensure the safe provision of services and, through active and close collaboration with Hyogo Medical University Hospital Orthopedic Surgery, contribute to the advancement of regenerative medicine. Please note that the Company holds various patents related to PFC-FD™, including preparation methods.

*Note: "PFC-FD™" is a trademark of CellSource Co., Ltd.

Department of Orthopedic Surgery of Hyogo Medical University Hospital

Since its establishment in 1972, Hyogo Medical University Hospital has consistently provided advanced medical care with the latest medical facilities and equipment. The Department of Orthopedic Surgery of the hospital covers specialized fields with teams dedicated to the spine, upper extremity, joint (hip, knee sports, knee arthroplasty, foot, osteoporosis), and tumors, providing treatment based on leading-edge knowledge and advanced technology. The hospital serves as a key regional hospital, striving to provide high-quality medical care in collaboration with surrounding medical institutions.

CellSource Co., Ltd.

CellSource specializes in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3240004) in accordance with the Act on the Safety of Regenerative Medicine, it has handled over 120,000 cell-related procedures. With a wealth of experience, it strives to offer reliable services to medical institutions and contribute to research and technological development.

Representative Chairman of the Board: Masayuki Yamakawa

Representative director and CEO: Takashi Sawada

Listed Market: Tokyo Stock Exchange, Prime Market (Securities Code: 4880)

Location: Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo

URL: <https://www.cellsourc.co.jp/en/>

Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete.

In the event of any translation error or misunderstanding, the original Japanese version shall prevail.